Is the targeted drug solidegib effective for basal cell carcinoma?

Basal cell carcinoma, as a malignant tumor originating from the basal cells of the skin, although its growth rate is relatively slow, if not treated in time, it may still pose a serious threat to the patient's health. Treatment of basal cell carcinoma is particularly complex for certain types of patients, such as those with Gorlin syndrome (also called nevoid basal cell carcinoma syndrome), because these patients may need dozens or even hundreds of surgeries throughout their lives to remove recurring cutaneous basal cell carcinomas (BCC).

Sonidegib (Sonidegib), an oral Hedgehog signaling pathway inhibitor, has been validated in clinical studies for its efficacy in treating Gorlin syndrome patients. In the pivotal BOLT trial, solidegib demonstrated impressive therapeutic effects. The trial showed that 88Gorlinpatients who received 800mg solidegib Pan> syndrome patients (total sample size 13 patients) experienced BCCs complete responses, meaning their tumors completely disappeared and did not relapse within a certain period of time. This result not only proves the effectiveness of solidegib in the treatment of Gorlin syndrome patients, but also provides a new treatment option for such patients.

In addition to its remarkable efficacy, the safety of Solidegib has also been evaluated in clinical trials. Although the adverse event rate in the BOLT trial was 88% in the solidegib group, this rate was similar to that seen in patients with sporadic BCC. This means that the incidence of adverse events of Solidegib has not been significantly increased due to the particularity of the patient population, thereby increasing confidence in its clinical application. Of course, for any drug, doctors need to weigh the efficacy and safety before formulating an individualized treatment plan for the patient.

Overall, solidegib, as a targeted drug, has demonstrated good efficacy and safety in the treatment of basal cell carcinoma in patients with Gorlin syndrome. However, it is worth noting that each patient's specific situation and reaction may be different, so when using Solidegib or any other drug, it should be done under the guidance of a doctor and pay close attention to the patient's reaction and changes in condition. At the same time, with the continuous deepening of medical research, more new drugs and treatment options may appear in the future, bringing better therapeutic effects and quality of life to basal cell carcinoma patients.

(Click to view an introduction to drugs for the treatment of basal cell carcinoma)

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC7211768/